BofA Securities downgraded Editas Medicine Inc EDIT, citing few value-driving catalysts in the near term.In its third-quarter earnings release, Editas Medicine said it engaged an investment bank to lead the process of partnering or out-licensing reni-cel (renizgamglogene autogedtemcel, previously EDIT-301).The company is developing reni-cel for sickle cell disease and transfusion-dependent Beta Thalassemia.The company is on track to share additional clinical and patient-reported outcomes data from 28 patien ...